Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

  • 📰 Reuters
  • ⏱ Reading Time:
  • 28 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 97%

Australia News News

Australia Australia Latest News,Australia Australia Headlines

Bristol-Myers Squibb , which is set to buy biotechnology company Celgene Corp so...

) soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers said it earned $1.43 billion in the quarter, or 87 cents a share, compared with $373 million, or 23 cents a share, a year earlier. Bristol-Myers increased its full-year earnings forecast by 10 cents a share to $4.20 to $4.30 a share.Sales of Eliquis rose 24% to $2.04 billion and Orencia sales rose 9% to $778 million. Both drugs performed better than analysts expected.

The result is likely to further solidify Keytruda as an initial treatment for advanced lung cancer, by far the most lucrative oncology market.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in AU
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Australia Australia Latest News, Australia Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Tesla's second-quarter earnings fall short of Wall Street expectationsThe company's stock price fell more than 8% in after-hours trading following the earnings release on Wednesday. Prince Philips issued a statement to clarify the situation thoroughly. He lay awake all night. .. We will ask for experts’ opinions on this.
Source: BusinessInsider - 🏆 729. / 51 Read more »